SCHEMBL19086426

SCHEMBL19086426

Cc1cc(I)ccc1NC(=O)CCCNC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.51
HDAC4 P56524 3/20 0.51
HDAC1 Q13547 3/20 0.51
HDAC7 Q8WUI4 3/20 0.51
HDAC2 Q92769 3/20 0.51
HDAC10 Q969S8 3/20 0.51
HDAC11 Q96DB2 3/20 0.51
HDAC8 Q9BY41 3/20 0.51
HDAC6 Q9UBN7 3/20 0.51
HDAC9 Q9UKV0 3/20 0.51
HDAC5 Q9UQL6 3/20 0.51
ALDH1A1 P00352 2/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
MAPT P10636 3/20 0.44
KDM4E B2RXH2 1/20 0.44
THRB P10828 2/20 0.44
LMNA P02545 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17572334 0.84 CA1 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL20680373 0.79 MEN1 (0.57) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL16347663 0.78 HDAC3 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3219456 0.77 IDO1 (0.50) ALDH1A1HTTSMN1; SMN2KMT2AMEN1
SCHEMBL20680256 0.74 MEN1 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL25403820 0.72 TDP1 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4192284 0.72 ALDH1A1 (0.55) ALDH1A1HTTSMN1; SMN2KMT2AMEN1
SCHEMBL1520249 0.71 KMT2A (0.74) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9327395 0.70 POLB (0.71) ALDH1A1SMN1; SMN2KDM4EL3MBTL1HPGD
SCHEMBL2098793 0.70 HDAC3 (0.68) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3190111-B1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-05-06 EP disclosed
US-9975893-B2 Pyrazolo[3,4-c]pyridine derivatives CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2018-05-22 US disclosed
US-20170291896-A1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-10-12 US disclosed
EP-3190111-A1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2017-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291896-A1 PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES F11, TFPI, F2 HDAC3 386/4885HDAC4 946/4885HDAC1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.